Guidelines on Penile Cancer

G. Pizzocaro (Chairman), F. Algaba, S. Horenblas, E. Solsona, S. Tana, H. Van Der Poel, N. Watkin

© European Association of Urology 2009
<table>
<thead>
<tr>
<th>TABLE OF CONTENTS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. INTRODUCTION</td>
<td>4</td>
</tr>
<tr>
<td>2. METHODOLOGY</td>
<td>4</td>
</tr>
<tr>
<td>2.1 References</td>
<td>4</td>
</tr>
<tr>
<td>3. DEFINITION OF PENILE CANCER</td>
<td>5</td>
</tr>
<tr>
<td>4. EPIDEMIOLOGY</td>
<td>5</td>
</tr>
<tr>
<td>4.1 References</td>
<td>6</td>
</tr>
<tr>
<td>5. RISK FACTORS AND PREVENTION</td>
<td>6</td>
</tr>
<tr>
<td>5.1 References</td>
<td>7</td>
</tr>
<tr>
<td>6. TNM CLASSIFICATION AND PATHOLOGY</td>
<td>8</td>
</tr>
<tr>
<td>6.1 TNM classification</td>
<td>8</td>
</tr>
<tr>
<td>6.1.1 References</td>
<td>9</td>
</tr>
<tr>
<td>6.2 Pathology</td>
<td>9</td>
</tr>
<tr>
<td>6.2.1 Penile biopsy</td>
<td>10</td>
</tr>
<tr>
<td>6.2.2.1 Pathological categories</td>
<td>10</td>
</tr>
<tr>
<td>6.2.2.2 Histology and metastatic risk</td>
<td>10</td>
</tr>
<tr>
<td>6.2.3 References</td>
<td>10</td>
</tr>
<tr>
<td>7. DIAGNOSIS AND STAGING</td>
<td>11</td>
</tr>
<tr>
<td>7.1 Primary lesion</td>
<td>11</td>
</tr>
<tr>
<td>7.2 Regional lymph nodes</td>
<td>11</td>
</tr>
<tr>
<td>7.2.1 Lymphatic drainage of the penis</td>
<td>11</td>
</tr>
<tr>
<td>7.2.2 Non-palpable nodes</td>
<td>12</td>
</tr>
<tr>
<td>7.2.3 Risk factors</td>
<td>12</td>
</tr>
<tr>
<td>7.2.4 Palpable nodes</td>
<td>12</td>
</tr>
<tr>
<td>7.3 Distant metastases</td>
<td>12</td>
</tr>
<tr>
<td>7.4 Guidelines for the diagnosis of penile cancer</td>
<td>13</td>
</tr>
<tr>
<td>7.5 References</td>
<td>13</td>
</tr>
<tr>
<td>8. TREATMENT</td>
<td>16</td>
</tr>
<tr>
<td>8.1 Primary tumour</td>
<td>16</td>
</tr>
<tr>
<td>8.1.1 Category Tis and Ta</td>
<td>16</td>
</tr>
<tr>
<td>8.1.2 Category T1G1</td>
<td>16</td>
</tr>
<tr>
<td>8.1.3 Category T1G2-3</td>
<td>16</td>
</tr>
<tr>
<td>8.1.4 Category T2 (of the glans)</td>
<td>17</td>
</tr>
<tr>
<td>8.1.5 Category T2 (of the corpora) and T3</td>
<td>17</td>
</tr>
<tr>
<td>8.1.6 Category T4</td>
<td>17</td>
</tr>
<tr>
<td>8.1.7 Local disease recurrence</td>
<td>17</td>
</tr>
<tr>
<td>8.1.8 Technical aspects</td>
<td>18</td>
</tr>
<tr>
<td>8.1.8.1 Conservative surgery</td>
<td>17</td>
</tr>
<tr>
<td>8.1.8.2 Radical amputation</td>
<td>17</td>
</tr>
<tr>
<td>8.1.9 Radiotherapy</td>
<td>17</td>
</tr>
<tr>
<td>8.1.9.1 Recommendations for radiotherapy</td>
<td>18</td>
</tr>
<tr>
<td>8.1.10 Guidelines for treatment strategies for primary tumour</td>
<td>18</td>
</tr>
<tr>
<td>8.2 Treatment of regional lymph nodes</td>
<td>19</td>
</tr>
<tr>
<td>8.2.1 Management of patients with non-palpable inguinal nodes</td>
<td>19</td>
</tr>
<tr>
<td>8.2.1.1 Surveillance</td>
<td>19</td>
</tr>
<tr>
<td>8.2.1.2 Prognostic factors</td>
<td>19</td>
</tr>
<tr>
<td>8.2.1.3 Sentinel node biopsy (SNB)</td>
<td>19</td>
</tr>
<tr>
<td>8.2.2 Management of patients with palpable inguinal nodes</td>
<td>19</td>
</tr>
<tr>
<td>8.2.2.1 Inguinal LAD</td>
<td>20</td>
</tr>
<tr>
<td>8.2.2.2 Modified inguinal LAD</td>
<td>20</td>
</tr>
<tr>
<td>8.2.2.3 The role of pelvic LAD</td>
<td>20</td>
</tr>
<tr>
<td>8.2.2.4 Video-endoscopic inguinal and pelvic LAD</td>
<td>20</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

The European Association of Urology (EAU) Guidelines Group on Penile Cancer has prepared this guidelines document to assist medical professionals in the management of penile cancer. The guidelines aim to provide detailed, up-to-date information, based on recent developments in our understanding and management of penile squamous cell carcinoma (SCC). However, it must be emphasised that these guidelines provide a standardised general approach to treating a patient and that the Guidelines provide guidance and recommendations without legal authority or implications.

Publication history information: The Penile Cancer Guidelines were first published in 2001 and updated in 2004, followed by this full text update in 2009.

2. METHODOLOGY

To update the last published guidelines in 2004, a meticulous PubMed literature search between October 2003 and October 2008 was carried out by all members of the Penile Cancer Consensus Group according to their field of interest (1). A total of 980 abstracts published on SCC of the penis were identified.

Only one evidence-based peer-reviewed document was published during the period 2004 to 2008. This was the physician data query (PDQ) on ‘Penile Cancer Treatment’ (Health Professional Version) published by the National Cancer Institute, National Institutes of Health (Bethesda, USA) (2). No randomised controlled trials or Cochrane reviews were published.

References used in the text have been assessed according to their level of scientific evidence (Table 1) and guideline recommendations have been graded (Table 2) according to the Oxford Centre for Evidence-based Medicine Levels of Evidence (3). The aim of grading recommendations is to provide transparency between the underlying evidence and the recommendation given.

Publication history: The EAU Penile Cancer Guidelines were first published in 2000. Partial updates were achieved in 2001 and 2004, followed by the current version which presents a full text update. Additionally, a quick reference guide is available. All texts can be viewed and downloaded for personal use at the society website: http://www.uroweb.org/professional-resources/guidelines/.

Table 1: Level of evidence

<table>
<thead>
<tr>
<th>Level</th>
<th>Type of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a</td>
<td>Evidence obtained from meta-analysis of randomised trials</td>
</tr>
<tr>
<td>1b</td>
<td>Evidence obtained from at least one randomised trial</td>
</tr>
<tr>
<td>2a</td>
<td>Evidence obtained from one well-designed controlled study without randomisation</td>
</tr>
<tr>
<td>2b</td>
<td>Evidence obtained from at least one other type of well-designed quasi-experimental study</td>
</tr>
<tr>
<td>3</td>
<td>Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports</td>
</tr>
<tr>
<td>4</td>
<td>Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities</td>
</tr>
</tbody>
</table>

Table 2: Grade of recommendation

<table>
<thead>
<tr>
<th>Grade</th>
<th>Nature of recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial</td>
</tr>
<tr>
<td>B</td>
<td>Based on well-conducted clinical studies, but without randomised clinical trials</td>
</tr>
<tr>
<td>C</td>
<td>Made despite the absence of directly applicable clinical studies of good quality</td>
</tr>
</tbody>
</table>

*modified from Sackett et al. (3)

2.1 REFERENCES


UPDATE MARCH 2009
3. DEFINITION OF PENILE CANCER

Penile cancer is a relatively rare SCC. It usually originates in the epithelium of the inner prepuce and glans. It shares a similar pathology and natural history with SCC of the oropharynx, female genitalia (cervix, vagina and vulva) and anus. Phimosis, poor hygiene and smoking are the major risk factors for penile cancer. Typing has been done of the human papillomaviruses (HPV) responsible for the sexual transmission of genital warts, condyloma acuminata SCC of the penis.

An improved understanding of the natural history of the disease, earlier diagnosis, better technology, research group collaboration and centralisation of patients in centres of excellence has improved the cure rate for penile cancer from 50% in the 1990s to 80% in 2008.

4. EPIDEMIOLOGY

In Western countries, primary malignant penile cancer is uncommon, with an incidence of less than 1.00 per 100,000 males in Europe and the United States of America (USA) (1, 2). There are, however, important geographical variations, with several European regions (Figure 1) reporting an incidence greater than 1.00 per 100,000 males (3). Incidence is also affected by race and ethnicity in North America (1), with the highest incidence of penile cancer found in white Hispanics (1.01 per 100,000), followed by Alaskan, Native/American Indians (0.77 per 100,000), Blacks (0.62 per 100,000) and White non-Hispanics (0.51 per 100,000).

In contrast, in the non-Western world, the incidence rate of penile cancer is much higher and can represent 10-20% of malignant disease in men ranging from an age-adjusted incidence of 0.7 to 3 per 100,000 people in India to 8.3 per 1000,000 men in Brazil and even higher in Uganda, where it is the most commonly diagnosed cancer.

Important risk factors include social and cultural habits, hygienic and religious practices (4). Penile carcinoma is rare in communities that practise circumcision in newborns or before puberty (Jews, Muslims and the Ibos of Nigeria). Early circumcision reduces the risk of penile cancer by 3 to 5 times. Adult circumcision does not protect against penile cancer.

In the USA, the overall age-adjusted incidence rate decreased considerably between 1973 and 2002 from 0.84 per 100,000 in 1973-1982 to 0.69 per 100,000 in 1983-1992 and further to 0.58 per 100,000 in 1993-2002 (1). In European countries, the incidence during the 1980s and 1990s was stable or increased slightly (2). The incidence rate continuously increases with age (2); however, the disease has been reported in younger men and in children.
4.1 REFERENCES


5. RISK FACTORS AND PREVENTION

Risk factors for penile cancer were identified by the Karolinska Institute from a Medline search of published literature from 1966-2000 (1). Strong risk factors (OR > 10) identified by case-control studies included (level of evidence: 2a):

- phimosis
- chronic inflammatory conditions, e.g. balanoposthitis, lichen sclerosus and atrophicus (balanitis xerotica obliterans)
- treatment with sporalene and ultraviolet A photochemotherapy.

Sexual history (multiple partners, early age of first intercourse) and a self-reported history of condylomata were associated with a 3- to 5-fold increased risk of penile cancer. Smoking is also a risk factor. Cervical cancer in the wife was not consistently associated with penile cancer in the husband.
In many case series, HPV DNA was identified in 70-100% intraepithelial neoplasia and in 40-50% of cases with invasive penile cancer. These results were confirmed by a population-based case control study (2). Among men not circumcised in childhood, phimosis was strongly associated with the development of invasive penile cancer (OR = 11.4; 95% CI 5.0-25.9), while cigarette smoking was associated with a 4.5-fold increased risk (95% CI 2.0-10.1). Human papillomavirus DNA was detected in 80% of tumour specimens; 69% were positive for HPV-16 (level of evidence: 2a).

Smegma as a carcinogen has been clearly excluded (3). The risk of cancer among patients with condyloma acuminata increased for vulva, vagina, penis and anus (4) (level of evidence: 2b). Human papillomavirus-16 and -18 have a causal role in 70% of cancers of the cervix, vagina and anus and about 30-40% of cancers of the vulva, penis and oropharynx. Other cofactors are very likely to be necessary for progression from HPV infection to cancer (5).

In June 2006, the US Food and Drug Administration (FDA) licensed the first vaccine to prevent cervical cancer and other HPV-associated diseases in women (6). The vaccine protects against infection with HPV-6, HPV-11, HPV-16 and HPV-18, which together are responsible for 70% of cervical cancers and 90% of genital warts. Human papillomavirus is highly transmissible, with a peak incidence soon after the onset of sexual activity. The recommended age for vaccination in females is 11-12 years (7), with catch-up vaccination recommended in females aged 13-26 years.

However, vaccination is not a substitute for routine cervical cancer screening and vaccinated females should continue to have cervical cancer screening. Vaccination against HPV has also been recommended in males (8). Although a study found that mid-adult (25 years or older) women have a high level of acceptance for HPV vaccination (9), only 33% of males wanted the HPV vaccine, 27% did not and 40% were undecided (10).

Interestingly, the presence of high-risk HPV DNA in penile cancer does not compromise prognosis. An early study (11) found no difference between HPV DNA-negative and HPV DNA-positive patients in lymph node metastases and 10-year survival rate. In a more recent study (12), disease-specific 5-year survival in the high-risk HPV-negative group was 78% versus 93% in the high-risk HPV-positive group (log rank test p = 0.03). This suggests the presence of high-risk HPV confers a survival advantage in patients with penile cancer. The virus plays an important role in oncogenesis through interaction with oncogenes and tumour suppressor genes (P53 and Rb-gene) (13).

5.1 REFERENCES

6. TNM CLASSIFICATION AND PATHOLOGY

6.1 TNM classification

The 2002 UICC Tumour Node Metastasis (TNM) classification (1) for penile cancer is shown in Table 3.

Table 3: 2002 TNM (Tumour, Node, Metastasis) classification of penile cancer

<table>
<thead>
<tr>
<th>T - Primary tumour</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TX Primary tumour cannot be assessed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T0 No evidence of primary tumour</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tis Carcinoma in situ</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ta Non-invasive verrucous carcinoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1 Tumour invades subepithelial connective tissue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2 Tumour invades corpus spongiosum or cavernosum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3 Tumour invades urethra or prostate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4 Tumour invades other adjacent structures</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N - Regional lymph nodes</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NX Regional lymph nodes cannot be assessed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0 No evidence of lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N1 Metastasis in a single inguinal lymph node</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N2 Metastasis in multiple or bilateral superficial lymph nodes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N3 Metastasis in deep inguinal or pelvic lymph nodes, unilateral or bilateral</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>M - Distant metastases</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>MX Distant metastases cannot be assessed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M0 No evidence of distant metastases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M1 Distant metastases</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This classification is in need of an update, particularly the definition of T2 category, as the prognosis of patients with tumour invasion of the corpus spongiosum is much better than invasion of the corpus cavernosum (2, 3).

Rees et al. (2) reported on 72 patients with T2 tumours. Both local recurrence (35% vs 17%) and mortality (30% vs 21%) rates were higher in patients with tunical or cavernosal involvement after a mean follow-up of 3 years (level of evidence: 2b). The authors proposed defining T2a patients by spongiosum-only invasion and T2b patients by involvement of tunica or corpus cavernosum.

However, a deeper analysis resulted in severe criticism and a new proposal for classification (3). A retrospective analysis of the records of 513 patients treated between 1956 and 2006 confirmed the above-mentioned difference between tumour invasion of corpus spongiosum and cavernosum. It also confirmed that there were no differences in long-term survival between T2 and T3, and no
significant differences between N1 and N2 in the 1987-2002 TNM classification (level of evidence: 2a). A new TNM classification was therefore proposed for T2, T3, T4 and N1, N2, N3 (Table 4) (3). In the new proposed classification, retroperitoneal node metastases are considered to be distant metastases as for the neck, lung and other visceral organs. The new classification is much more appropriate than the present TNM categories, but it needs to be confirmed by UICC.

Table 4: Proposed modification to 1987-2002 TNM classification*

<table>
<thead>
<tr>
<th>T - Primary tumour</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>tX, T0, Tis, Ta and T1 Unchanged</td>
<td></td>
</tr>
<tr>
<td>T2 Tumour invades corpus spongiosum</td>
<td></td>
</tr>
<tr>
<td>T3 Tumour invades corpus cavernosum</td>
<td></td>
</tr>
<tr>
<td>T4 Tumour invades adjacent structures (e.g. urethra, prostate)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N - Regional lymph nodes</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Nx and N0 Unchanged</td>
<td></td>
</tr>
<tr>
<td>N1 Unilateral inguinal metastases, mobile</td>
<td></td>
</tr>
<tr>
<td>N2 Bilateral inguinal metastases</td>
<td></td>
</tr>
<tr>
<td>N3 Fixed inguinal metastases or metastases in pelvic lymph nodes</td>
<td></td>
</tr>
</tbody>
</table>

*From Leijte et al. (2008) (3).

6.1.1 References


6.2 Pathology

Squamous cell carcinoma accounts for more than 95% of cases of malignant disease of the penis. Malignant melanomas and basal cell carcinoma are much less common. It is not known how often SCC is preceded by premalignant lesions (1). Although SCC is the most common penile neoplasia, different types and varying growth patterns have been identified (2-4) (Tables 5 and 6).

Table 5: Premalignant lesions

Lesions sporadically associated with SCC of the penis
- Cutaneous horn of the penis
- Bowenoid papulosis of the penis
- Balanitis xerotica obliterans (lichen sclerosus et atrophicus)

Lesions at high risk of developing SCC of the penis (up to one-third transform to invasive SCC)
- Penile intraepithelial neoplasia (carcinoma in situ): erythroplasia of Queyrat and Bowen’s disease

LE = level of evidence; SCC = squamous cell carcinoma.

Table 6: Penile SCC

Types of SCC
- Classic
- Basaloid
- Verrucous and its varieties (2):
  - Warty (condylomatus) carcinoma
  - Verrucous carcinoma
  - Papillary carcinoma
  - Hybrid verrucous carcinoma
  - Mixed carcinomas (warty basaloid, adenobasaloid carcinoma)
- Sarcomatoid
- Adenosquamous
Growth patterns of SCC
- Superficial spread
- Nodular or vertical-phase growth
- Verrucous

Differentiation grading systems for SCC
- Broders’ system (5)
- Maiche’s system score (6)

SCC = squamous cell carcinoma.

6.2.1 Penile biopsy
There is no need for biopsy if:
- There is no doubt about the diagnosis and/or
- Treatment of the lymph nodes is postponed after treatment of the primary tumour and/or after histological examinations of the sentinel node(s).

There is a need for histological confirmation if:
- There is doubt about the exact nature of the lesion (metastasis, melanoma, etc)
- Treatment of the lymph nodes is based on pre-operative histological information (risk-adapted strategy).

In these cases an adequate biopsy is advised. When performing a biopsy, it is important to consider the findings from a study of biopsy size. The study of biopsies with an average size of 1.1 cm found there was:
- difficulty in evaluating the extent of depth in 91% of biopsies
- discordance between the grade at biopsy and the final specimen in 30% of cases
- failure to detect cancer in 3.5% (1)
- Thus, although a punch biopsy may be sufficient for superficial lesions, an excisional biopsy is preferred.

6.2.2.1 Pathological categories
Traditionally, squamous cell carcinomas were considered as superficial or invasive. However, Cubilla et al. (2) has divided penile carcinoma into four categories:
- superficial spreading
- vertical growth
- verrucous
- multicentric.

Different types of growth have different prognoses (3) and different ways of dissemination. The limits of surgical partial resections must therefore be set according to the growth pattern at the time of evaluation of the frozen sections (4). If the margins are studied following these criteria (including urethral and periurethral tissue), only 3-4 mm of tumourfree tissue is sufficient to consider the surgical margins to be negative (7). Basaloid SSC is a cellular subtype that is better recognised than before. It is highly aggressive. (8)

6.2.2.2 Histology and metastatic risk
Histological subtypes carry different risks of developing metastatic lymph nodes:
- condylomatous: 18.2%
- SCC: 56.7%
- sarcomatoid carcinoma: 89% (9).

Similarly, invasion pattern (10) and vascular invasion (10, 11) are correlated with lymph node metastases, with 23.1% of positive lymph nodes associated with a nodular pattern and 64.6% with an infiltrative pattern.

6.2.3 References


7. **DIAGNOSIS AND STAGING**

The primary tumour and regional lymph nodes must be staged correctly to enable the most appropriate treatment.

7.1 **Primary lesion**

Physical examination of a patient with penile cancer includes:
- diameter of the penile lesion(s) or suspicious areas
- location of lesion(s) on the penis
- number of lesions
- morphology of lesion(s): papillary, nodular, ulcerous or flat
- relationship of lesion(s) to other structures, e.g. submucosa, tunica albuginea, urethra,
- corpus spongiosum and corpus cavernosum
- colour and boundaries of lesion(s)
- penis length.

Accurate histological diagnosis and staging of both the primary tumour and regional nodes are necessary in making treatment decisions (1). In a small series, physical examination alone was more reliable than imaging with ultrasound and/or MRI to judge infiltration into the corpora (2). Artificial erection with prostaglandin E1 (alprostadil) in combination with magnetic resonance imaging (MRI) was helpful in identifying the depth of tumour invasion of the corpora cavernosa and whether or not conservative surgery should be used (3, 4).

7.2 **Regional lymph nodes**

7.2.1 **Lymphatic drainage of the penis**

Primary lymphatic drainage of penile cancer occurs to the inguinal nodes. A recent imaging study (5) has
shown that all sentinel nodes are located in the superior and central inguinal zones with most found in the
medial superior zone. No lymphatic drainage was observed from the penis to the inferior two regions of the
groin and no direct drainage to the pelvic nodes was visualised. These findings confirm earlier studies (6-8).

7.2.2 Non-palpable nodes
A careful inguinal physical examination is necessary. In the absence of palpable abnormalities, an inguinal
ultrasound (7.5 mHz) may reveal abnormal nodes and can be used as a guide for fine-needle aspiration biopsy
(9, 10). A sentinel node biopsy (SNB) (8) is not recommended because of a high rate of false-negative results
(25%, range 9-50%) (11). However, recent reports suggest that dynamic SNB (using isosulphan blue and/or
technetium-99m (99mTc)-colloid sulphur) improved survival compared to a ‘wait-and-see’ policy (level of
evidence: 3) and reduced toxicity compared to inguinal lymphadenectomy (LAd) (12, 13). A prospective study
found dynamic SNB had 100% specificity and 78-80% sensitivity (14-18) (level of evidence: 2a). As analysis
of dynamic SNB is operator-dependent (19) and relies on experience, the procedure is only available in a few
centres. Because iliac lymph node metastases do not occur in the absence of inguinal metastases (19), an
abdominal computed tomography (CT) scan is not necessary in patients with no inguinal node metastases.

A conventional CT or MRI scan cannot detect micrometastases (20). Large studies are required to
confirm promising results reported with nanoparticle-enhanced MRI and positron emission tomography (PET)
or CT imaging (21, 22).

7.2.3 Risk factors
The presence of lymph node metastases may be predicted from tumour characteristics other than T and G
categories. Risk factors identified from retrospective studies include pathological subtype, perineural invasion,
lymphovascular invasion, tumour depth or thickness, anatomical site, size and growth pattern, front of invasion,
positive margins and urethral invasion (23). Several large series have identified lymphovascular invasion alone
(24), lymphovascular invasion plus absent koilocytosis (25), lymphovascular invasion plus palpable inguinal
nodes (26), high histological grade plus perineural invasion (27). The most important adverse pathological
prognostic factors appear to be perineural invasion, vascular invasion and high histological grade (23).
Nomograms can be used to evaluate the predictive power of clinical and pathological indicators (23, 26).

7.2.4 Palpable nodes
Palpable nodes should be described as follows:
• node consistency
• node location(s)
• diameter of node(s) or mass(es)
• unilateral or bilateral localisation
• number of nodes identified in each inguinal area
• mobile or fixed nodes or masses
• relationship (e.g. infiltration, perforation, etc) to other structures, such as the skin or Cooper ligament
• oedema on leg and/or scrotum.

Lymph node metastases in palpable nodes can be diagnosed using a percutaneous needle aspiration biopsy
(cytology and/or histology puncture). At the time of diagnosis of penile cancer, as many as 50% of palpable
inguinal nodes will be reactive rather than due to lymph node metastasis. In contrast, during follow-up, nearly
100% of enlarged nodes are metastatic (28-30) (level of evidence: 2a).

Thus, after allowing time for inflammatory reactions to subside, regional nodes should be evaluated
within a few weeks after treatment of the primary tumour. Histological diagnosis can be done using fine-needle
aspiration biopsy, tissue core biopsy or open biopsy, according to the preference of the pathologist (31, 32)
(level of evidence: 2b). In the case of a negative biopsy and clinically suspicious nodes, a repeat biopsy or
excisional biopsy should be performed.

Imaging techniques (CT, MRI) are widely used, but are only useful for staging in patients with proven lymph
node metastases. So far no imaging modality can identify microscopic invasion. Imaging using PET (33) and
the use of molecular biology are under investigation (34, 35).

7.3 Distant metastases
An assessment of distant metastases should be performed in patients with proven positive inguinal
nodes (36) (level of evidence: 2b). Pelvic or abdominal CT scan should be used to identify
pelvic (and retroperitoneal) adenopathies in patients with inguinal metastases. While this is not a very reliable
diagnostic method, the detection of pelvic masses has a considerable impact on therapy and prognosis (39).
Routine blood determination and chest X-rays are usually performed, despite the fact that lung metastasis
is exceptionally rare. The value of SCC antigen determination as a staging tool is unclear and therefore not recommended for routine use (34). Biological studies are investigational (37).

A diagnostic schedule is summarised in Table 7.

Table 7: Diagnostic schedule for penile cancer

<table>
<thead>
<tr>
<th>Lesion level</th>
<th>Mandatory</th>
<th>Advisable</th>
<th>Optional</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary tumour</td>
<td>Physical examination</td>
<td>Cytology or histology</td>
<td>MRI Ultrasound</td>
</tr>
<tr>
<td>Regional disease</td>
<td>Physical examination</td>
<td>Dynamic sentinel node biopsy*</td>
<td>Ultrasound</td>
</tr>
<tr>
<td>Non-palpable nodes</td>
<td>Cytology or histology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palpable node</td>
<td>Ultra-sound (FNAC)*</td>
<td>Cytology or histology</td>
<td></td>
</tr>
<tr>
<td>Distant metastases</td>
<td>Pelvic CT, if positive</td>
<td>Abdominal CT</td>
<td>Bone scan in symptomatic patients</td>
</tr>
<tr>
<td>(chest X-rays)</td>
<td>(inguinal nodes)</td>
<td>(*99mTc) colloid sulphur</td>
<td>patients</td>
</tr>
</tbody>
</table>

FNAC = fine needle aspiration biopsy; MRI = magnetic resonance imaging; PGE1 = prostaglandin E1; CT = computed tomography.

Regional lymph nodes are the regional disease.

7.4 Guidelines for the diagnosis of penile cancer

<table>
<thead>
<tr>
<th>Primary tumour</th>
<th>GR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical examination</td>
<td></td>
</tr>
<tr>
<td>Mandatory</td>
<td>B</td>
</tr>
<tr>
<td>Cytological diagnosis</td>
<td></td>
</tr>
<tr>
<td>is mandatory</td>
<td>B</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Regional lymph node disease</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical examination</td>
<td></td>
</tr>
<tr>
<td>Mandatory</td>
<td>B</td>
</tr>
<tr>
<td>If nodes are non-palpable, ultrasound-guided FNAB</td>
<td></td>
</tr>
<tr>
<td>Optional</td>
<td></td>
</tr>
<tr>
<td>FNAB tumour-negative</td>
<td>B</td>
</tr>
<tr>
<td>If nodes are palpable</td>
<td></td>
</tr>
<tr>
<td>mandatory to record nodal morphological and physical characteristics and to perform FNAB for histological diagnosis</td>
<td>B</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Distant metastasis (beside inguinal nodes)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A pelvic CT scan is indicated if metastatic inguinal nodes are present</td>
<td>B</td>
</tr>
<tr>
<td>An abdominal CT scan and chest X-ray are advisable if pelvic CT scan is positive</td>
<td>B</td>
</tr>
<tr>
<td>A bone scan is advisable in M1 symptomatic patients</td>
<td>C</td>
</tr>
<tr>
<td>Biological laboratory determinations for penile cancer are investigational</td>
<td>None</td>
</tr>
</tbody>
</table>

GR = grade of recommendation, MRI = magnetic resonance imaging; PGE1 = prostaglandin E1; CT = computed tomography.

7.5 REFERENCES


UPDATE MARCH 2009


8. **TREATMENT**

The primary tumour and regional lymph nodes are usually treated separately. It is important to avoid both overtreatment, which may lead to side-effects, and undertreatment, which may impair survival.

8.1 **Primary tumour**

8.1.1 **Category Tis and Ta**

Tis and Ta are superficial lesions that can be treated with several conservative techniques:

- topical 5-fluorouracil for Tis (1)
- imiquimod 5% cream, an immune response modifier with good cosmetic and functional results on flat lesions (2)
- laser therapy with carbon dioxide (CO2) or neodymium-yttrium-aluminum-garnet (Nd:YAG) lasers (3, 4)
- photodynamic therapy (5)
- Mohs’ micrographic surgery for Ta lesions (6, 7).

However, conservative treatment may not be suitable in cases of multifocal lesions, which are responsible for 15% of recurrences. Total treatment of the glans surface combined with concomitant circumcision is strongly recommended (4) to avoid multiple recurrences (grade of recommendation: A). Cure with secondary healing was obtained in 94% of 106 Tis patients treated with peniscopically controlled CO2 laser excision. However, five patients had multiple recurrences and two required penile amputation (7). A recent paper on photodynamic therapy reported seven responses in 10 treated patients, but only four patients were recurrence-free after a mean follow-up of 35 months (5). Non-invasive verrucous carcinoma (Ta) needs a correct pre-operative diagnosis to avoid unnecessary extensive surgery (6). Furthermore, a recent report on Mohs’ micrographic surgery demonstrated a significant local recurrence rate for Tis and verrucous carcinoma as well as invasive SCC (7). In conclusion, the best results are achieved with laser surgery (level of evidence: 2b; grade of recommendation: B).

8.1.2 **Category T1G1**

For lesions limited (level of evidence: 2a) to the foreskin and sulcus, wide local excision with circumcision may provide adequate treatment. Pathological assessment of the surgical margin is mandatory; a margin of 3-4 mm is sufficient (8). For T1 tumours of the glans, peniscopically controlled CO2 laser excision alone cured 86% of 78 patients with histologically superficial infiltration (≤ 1 mm) of lamina propria (4). Another 40 patients had deeper infiltration (> 1 mm) with exophytic warty-like or plaque tumours. These patients received neo-adjuvant vincristine, bleomycin and methotrexate (VBM) chemotherapy, with cure achieved in 33 (82%) patients. Of 18 (15%) relapsed patients, only eight (7%) needed penile amputation or radiotherapy (level of evidence: 2b). An alternative treatment of glans resurfacing (9) has shown promising results for preinvasive lesions (level of evidence: 2a).

8.1.3 **Category T1G2-3**

For patients who can guarantee they will attend for regular follow-up, a penis-preserving strategy is strongly recommended using wide local laser excision plus reconstructive surgery (10, 11) or glansectomy (12-14) (level of evidence: 2a). Treatment choice is influenced by tumour size and position on the glans and the side-effects of treatment. Meticulous follow-up is essential to enable immediate treatment of any local disease recurrence.

There is no difference in the local recurrence rate (15% or more) between external radiation therapy, interstitial brachytherapy (BRT) laser therapy and wide local excision. Glansectomy has the lowest recurrence rate of 2% (13). Pathological assessment of surgical margins is essential when using these procedures to reduce the rate of local recurrence (12, 13, 15) (level of evidence: 2b).

Generally, early diagnosis of local recurrence does not have a negative impact on survival (16) (level of evidence: 3).
8.1.4  Category T2 (of the glans)
A conservative strategy of total glansectomy, with or without resurfacing of the corporeal heads, is recommended (5, 14) (level of evidence: 2a). Partial glansectomy is an alternative in very carefully selected patients with tumours that include less than half of the glans and in whom close follow-up is possible (17) (level of evidence: 2b). Consider partial amputation in patients unfit for more conservative reconstructive surgery (13).

8.1.5  Category T2 (of the corpora) and T3
For tumours involving the tips of the corpora, partial amputation is standard treatment (18, 19) (level of evidence: 2a). Reconstrutive surgery with negative margins at frozen section analysis is an alternative in carefully selected patients (level of evidence: 2b). For large tumours involving more than the distal corpora, partial or radical amputation is standard (level of evidence: 2a).

Traditionally, partial amputation has required removal of 2-cm tumour-free margins. This is almost certainly more than is necessary. However, it is essential to achieve tumour-free margins with pathological confirmation. A surgical margin of 5-10 mm is safe (15, 20, 21) (level of evidence: 2b).

8.1.6  Category T4
Deeply infiltrating tumours involving adjacent structures are often associated with disseminated disease at presentation and a short life expectancy. Palliative care may be most appropriate. In selected cases, down-staging with chemotherapy may be considered prior to total penectomy. Alternatives include surgery with adjuvant external beam irradiation (level of evidence: 3).

8.1.7  Local disease recurrence
For local recurrence after conservative therapy, a second conservative procedure is strongly advised if there is no corpora cavernosa invasion (22) (level of evidence: 2b). However, if there is a large or deep infiltrating recurrence, partial or total amputation is strongly recommended. The incidence of local recurrence increases with penis preservation, but can be treated in most cases. Local recurrence after penile amputation has a poor prognosis (23). Combined chemotherapy and radiotherapy as for advanced head and neck cancer has not yet been tried.

8.1.8  Technical aspects of surgery
8.1.8.1  Conservative surgery
The most important factors in the choice of conservative management are simplicity, morbidity of the procedure and the surgeon’s experience. Small areas of ablated/excised epithelium can heal without grafting. For a larger area, a skin graft provides a better cosmetic result in a shorter time (level of evidence: 3).

8.1.8.2  Partial/total amputation
Stenosis of the neo-meatus or perineal urethrostomy is seen in approximately 7-10% and can be prevented by a spatulated repair. Orchidectomy should not be performed routinely (level of evidence: 3).

8.1.9  Radiotherapy
External beam irradiation (ERT), brachytherapy (BRT) or both techniques together can be used. The ERT treatment is delivered with high-energy photons (4-6 MV) and uses CT scanning to define the target volume and to optimise dosage distribution. Different types of BRT can be used including external isotope mould, low-dose rate BRT, pulse-dose rate BRT or high-dose rate BRT.

Primary tumour radiotherapy is an alternative organ-preserving approach with excellent results in selected patients with T1-2 lesions less than 4 cm in diameter (level of evidence: 2a). There have been no prospective studies or randomised trials to evaluate the different modalities of radiation treatment.

A local control rate of about 60% has been reported using ERT, while BRT has achieved better control rates ranging from 70% to 90% (24-28). However, it is difficult to compare results using ERT and BRT because patients with large volume lesions (> 4 cm) are excluded from BRT. In addition, the different dosages used in different retrospective studies, even within the same institution, make it very difficult to compare results and side-effects.

Local failure rates after radiotherapy were higher than after adequate partial penectomy, but salvage surgery can restore local control (28, 29). The high doses of radiation needed to achieve local control can cause iatrogenic complications. Urethral stenosis (20-35%), glans necrosis (10-20%) and late fibrosis are the most serious types of tissue damage and can result in a non-functioning penis.
The penile preservation rate after radiotherapy is approximately 80%. The local control rate after Brt was recently reported as 90%, with an actuarial penile preservation rate of 87% at 5 years (29). Because of post-radiation changes (necrosis, scars, ulcers), it may be difficult to differentiate radiation sequelae from persistent or recurrent tumour and very close follow-up is recommended.

8.1.9.1 Recommendations for radiation therapy
Radiotherapy should be considered in two groups of patients with two different aims:

- **Organ-preserving treatment**: in men with T1-2 glans or coronal sulcus lesions (<4 cm), who are compliant for close follow-up. Both ERT combined with a Brt boost, or Brt alone, may be used to deliver the prescribed dose (>60 Gy).
- **Palliative radiotherapy**: in men with advanced or metastatic disease requiring palliative local treatment, the treatment of choice is ERT (40-50 Gy).

8.1.10 Guidelines for treatment strategies in primary tumour

<table>
<thead>
<tr>
<th>Primary tumour</th>
<th>LE</th>
<th>GR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category: Tis and Ta</td>
<td>Conservative therapy: CO₂ or Nd:YAG lasers surgery are recommended</td>
<td>2a</td>
</tr>
<tr>
<td>Multifocal lesions and HPV-16 infection</td>
<td>Total glans resurfacing and circumcision are strongly recommended to prevent multiple recurrences</td>
<td>2a</td>
</tr>
<tr>
<td>Category T1G1</td>
<td>T1G1 tumours are suitable for conservative surgery</td>
<td>2a</td>
</tr>
<tr>
<td></td>
<td>For glans lesions, CO2 laser surgery or resurfacing are appropriate</td>
<td>2a</td>
</tr>
<tr>
<td></td>
<td>For lesions of foreskin and sulcus, wide local excision with circumcision are appropriate with assessment of surgical margins</td>
<td>2a</td>
</tr>
<tr>
<td></td>
<td>Deeper infiltration may need adjuvant chemotherapy</td>
<td>2a</td>
</tr>
<tr>
<td>Category T1G2-3</td>
<td>Penile-preserving treatment with wide local laser excision for complying patients with follow-up, or glansectomy are indicated</td>
<td>2a</td>
</tr>
<tr>
<td></td>
<td>Assessment of surgical margins reduces rate of local recurrence</td>
<td>2b</td>
</tr>
<tr>
<td></td>
<td>In these cases early diagnosis of local recurrence does not have an adverse impact on survival</td>
<td>2b</td>
</tr>
<tr>
<td>Category T2 (of glans)</td>
<td>Total glansectomy, with or without resurfacing of corporeal heads</td>
<td>2a</td>
</tr>
<tr>
<td></td>
<td>Partial glansectomy is an alternative in very carefully selected patients with tumours less than half the glans and suitable for follow-up</td>
<td>2b</td>
</tr>
<tr>
<td></td>
<td>Consider partial amputation in patients unfit for follow-up</td>
<td>2b</td>
</tr>
<tr>
<td>Category T2 (of the corpora) and T3</td>
<td>Moderate partial amputation for tumours involving only tips of the corpora</td>
<td>2a</td>
</tr>
<tr>
<td></td>
<td>Partial or total amputation for larger tumours involving more than the distal corpora</td>
<td>2a</td>
</tr>
<tr>
<td></td>
<td>Traditionally, partial amputation has required removal of 2-cm tumour-free margins. A surgical margin of 5-10 mm is safe with pathological confirmation</td>
<td>2b</td>
</tr>
<tr>
<td>Category T4</td>
<td>Deeply infiltrating tumours involving adjacent structures are often associated with disseminated disease at presentation. For patients in poor conditions with short life expectancy, palliative radiotherapy may be most appropriate</td>
<td>2a</td>
</tr>
<tr>
<td></td>
<td>Some patients may be suitable for down-staging with chemotherapy prior to surgery. Alternatives include adjuvant external beam irradiation if surgery is not possible.</td>
<td>2a</td>
</tr>
<tr>
<td>Local disease recurrence after conservative therapy</td>
<td>Local recurrence is more likely with penis preservation but it is usually treatable</td>
<td>2a</td>
</tr>
<tr>
<td></td>
<td>Second conservative procedure is strongly advised in absence of corpora cavernosa invasion</td>
<td>2a</td>
</tr>
<tr>
<td></td>
<td>Partial or total amputation is strongly recommended for large or deep infiltrating recurrence</td>
<td>2a</td>
</tr>
</tbody>
</table>
Local recurrence after penile amputation has a poor prognosis 2a B

<table>
<thead>
<tr>
<th>Main uses of radiotherapy</th>
<th>Organ-preserving treatment in selected patients with T1-2 glans or coronal sulcus lesions &lt; 4 cm</th>
<th>2b B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Palliative in advanced or metastatic disease not responsive to chemotherapy</td>
<td>2b B</td>
</tr>
</tbody>
</table>

8.2 Treatment of regional lymph nodes

Lymphadenectomy is the necessary surgical procedure for patients with inguinal lymph node metastases. Bilateral LAD is often followed by prolonged lymph leakage, which can result in leg and scrotal lymphoedema. Other surgical complications include skin flap necrosis, wound infection and haemorrhage from exposed femoral vessels.

The procedure requires careful skin flap management, meticulous lymph node dissection, prophylactic antibiotics, compressive stoking and early ambulation. These complications occur in 30-70% of patients. Lymphadenectomy should therefore preferably only be performed in a therapeutic setting, where removal of lymph node metastases is indisputable.

8.2.1 Management of patients with non-palpable inguinal nodes

8.2.1.1 Surveillance

In the past, patients with low-stage tumours and clinically unaffected inguinal nodes have often undergone surveillance strategies. The 2004 EAU guidelines ‘strongly’ recommended surveillance only in patients with superficial and well-differentiated tumours: Tis, TaG1-2, T1G1 and T1G2 with superficial growth and no vascular invasion (30). This approach was criticised following a study that found 82% of 100 consecutive patients had undergone unnecessary prophylactic LAD (31).

8.2.1.2 Prognostic factors

For a long time, urologists have been oriented to look at pathological risk factors for metastases and pT3-T4 and all G3 patients were unequivocal candidates for bilateral LAD. In an old series (32), nodal metastases were found in 100% of pT3-T4, in 82% of pT2 and 23% of pT1. In particular, 16.5% of metastases were found in pT1G1 and 60% in pT1G2-3. No metastases were found in Ta or Tis. In a very recent series (33), lymph node metastases were found in 12% of pT1G2, a category that has therefore been defined as ‘intermediate risk’. A high histological grade and perineural invasion (21) or depth of invasion (34) are significant predictors of lymph node metastases. A nomogram (34) has identified palpable groin lymph nodes and vascular and/or lymphatic invasion as the most important predictors of lymph node metastases. A new nomogram with a larger international series of patients is ongoing (level of evidence: 2b).

8.2.1.3 Sentinel node biopsy (SNB)

Catalona’s SNB (35) was a failure, but dynamic SNB appears very promising (36-39). The concept behind dynamic SNB assumes there is a stepwise and orderly progression of the primary node (the so-called sentinel node) to secondary lymph nodes. There may be more than one sentinel node. To identify the sentinel node(s), 99mTc-nanocolloid is injected around the penile tumour intradermally the day before surgery. The sentinel lymph node(s) are detected intra-operatively with a gamma X-ray detection probe and patent blue dye staining before being dissected and removed. If there is a positive histology, either on frozen section or definitive histology, a formal complete inguinal LAD is performed.

The technique has been extensively studied in a few specialised centres. The Netherlands Cancer Institute group initially reported a high rate of false-negative cases (36). However, following modification of the technique, they reported a markedly reduced false-negative rate of 4.8% (39). However, the technique has been criticised for its steep learning curve and the need for the surgeon to perform a minimal number of 20 procedures per year (40) (level of evidence: 2a).

8.2.2 Management of patients with palpable inguinal nodes

In patients with penile cancer, moderately enlarged palpable inguinal nodes, which are not fixed, may or may not signify metastatic disease. The rate of false-positive nodes has been reported as high as 50% (41), but recently much lower figures of 30% have been reported (42). Ultrasound with fine-needle aspiration biopsy provides an excellent, rapid and easy way to detect metastatic involvement. Of course this is only reliable in tumour-positive patients. In suspected cases with tumour-negative findings, fine-needle aspiration biopsy should be repeated. Dynamic SNB is not reliable in this group of patients and should not be used (43, 44).

Thus, in all tumour-positive patients, early LAD should be performed (45, 46); bilateral LAD is the standard.
procedure. In contralateral non-palpable lymph nodes, surgical staging is recommended either by dynamic SNB or lymph node dissection (level of evidence: 2a).

8.2.2.1 Inguinal LAD
Significant morbidity has been described including wound infection, skin necrosis, wound dehiscence, lymphoedema and lymphocele (47, 48). Optimal skin handling and careful dissection of skin flaps are two of the most important factors in preventing complications. Skin rotation flaps and myocutaneous flaps should be used for primary wound closure in advanced cases (49) (level of evidence: 2b).

8.2.2.2 Modified inguinal LAD
This procedure is associated with less morbidity than standard LAD (50, 51). The rate of early complications was 6.8% (vs 41.4%) and the rate of late complications was 3.4% (vs 43.1%) for patients with modified LAD (51). However, reducing the field of dissection increased the possibility of false-negative cases (level of evidence: 2b).

The high false-negative rate described by Lopes et al. (52) should be considered in the light of recent findings concerning lymphatic drainage to the lateral superior Daserler’s zone, which was not dissected in this approach (53, 54). Current knowledge of lymphatic drainage at the penis suggests that a contemporary modified LAD should dissect the central and both superior Daserler’s zones of the inguinal region (grade of recommendation: B).

8.2.2.3 The role of pelvic LAD
There is no direct lymphatic drainage from penile cancer to the pelvic lymph nodes (54, 55). Thus, if there is no involvement of inguinal nodes, pelvic LAD is not warranted. In contrast, if the Cloquet node or other two inguinal nodes are involved on one side, a contemporary pelvic lymph node dissection must be performed through an upward muscle-splitting incision. Pathological predictors for the potential involvement of pelvic nodes in patients with involved inguinal nodes are the number of positive inguinal lymph nodes and extracapsular extent of metastatic disease (56) (level of evidence: 2a).

Pelvic LAD may be necessary as a secondary procedure. If bilateral dissection is indicated, it can be performed through a midline suprapubic extraperitoneal incision. The rate of positive pelvic nodes was 23% in cases with no more than two positive inguinal nodes and 56% for more than two positive inguinal nodes or if there is extracapsular extent in at least one inguinal node (57-59).

If very aggressive histological subtypes of penile cancer (i.e. basaloid) are present, or there is strong expression of p53, pelvic lymph node dissection should be considered if any inguinal node is involved (60) (grade of recommendation: B).

8.2.2.4 Video-endoscopic inguinal and pelvic LAD
This recently described technique is derived from laparoscopic surgery and has been evaluated only in small pilot studies (61, 62). It seems to carry a lower risk of skin complications, but a higher risk of lymphocele formation compared to an open approach; the reported overall complication rate was 23% (63). The reliability of this technique has not yet been assessed (level of evidence: 4).

Laparoscopic pelvic node dissection for bilateral pelvic lymph node removal, following positive bilateral inguinal LAD, is a rational approach, but only if the dissection can be performed with similar accuracy as open surgery.

8.2.3 Adjuvant chemotherapy
Adjuvant chemotherapy after resection of nodal metastases has been reported in a few series. There has been only one study group who reported consistent results with adjuvant post-operative chemotherapy in N+ patients (64, 65). Twenty-five consecutive patients with resected lymph node metastases from SCC of the penis received 12 weekly courses of adjuvant VBM (vincristine, bleomycin, methotrexate) chemotherapy between 1979 and 1990. All patients underwent ilioinguinal lymph node dissection and received adjuvant chemotherapy. Only four (16%) patients relapsed, and the other 21 had a long-term disease-free survival of 84%. These results compared favourably with a previous series of 31 patients, who underwent ilioinguinal lymph node dissection, alone or with adjuvant radiotherapy, between 1960 and 1978. The 5-year disease-free survival was only 37%. Among these 31 patients, only the involvement of a single, intranodal inguinal node metastasis was associated with good prognosis. In contrast, in the series of 25 patients treated with adjuvant chemotherapy (VBM), only bilateral and/or pelvic node involvement were significantly associated with poor prognosis, with 4 of 8 patients dying of penile cancer (level of evidence: 2a).
Since 1991, pN2-N3 patients have been treated with three courses of adjuvant cisplatin and 5-fluorouracil (PF) with only two relapses (6.7%) in the first 30 treated patients (65) (level of evidence: 2a).

8.2.4 Management of patients with fixed or relapsed inguinal nodes
Fourteen patients were treated with locally advanced or metastatic penile cancer with cisplatin, methotrexate and bleomycin (BMP) chemotherapy on days 2 to 5 (66). Toxicity was severe. Only three of the eight partial responders underwent surgery, while another two entered complete remission. In a confirmatory study by the Southwest Oncology Group (SWOG) (67), only six of 40 evaluable patients completed chemotherapy. Five complete and eight partial remissions were achieved, but at the cost of 11% treatment-related mortality and 17% life-threatening toxicity.

Another study (68) of BMP chemotherapy in 13 patients reported one death from treatment-related toxicity and no complete remissions (level of evidence: 2a).

A review was performed of 20 patients who had received neo-adjuvant chemotherapy, including BMP, for unresectable lymph node metastases during the period 1972 to 2005 (69). Twelve of 19 evaluable patients showed an objective tumour response. Five different chemotherapeutic regimens were used. Nine responders underwent subsequent surgery, of whom eight became long-term survivors without evidence of recurrent disease. Chemotherapy-related toxicity was fatal in three out of 10 patients treated with BMP (level of evidence: 2b).

At the MD Anderson Cancer Center (Houston, TX, USA) (70), 10 patients were treated with surgical consolidation following a stable, partial, or complete response to four to five courses of the following chemotherapeutic regimens: paclitaxel, ifosfamide and cisplatin (ITP) in five patients, paclitaxel and carboplatin (PC) in two patients, and BMP in three patients. Three of the five patients treated with ITP had a pathologically documented complete remission and two of them are long-term survivors. The two patients treated with PC became disease-free after post-chemotherapy surgery. All three patients treated with BMP suffered severe toxicity and died of the disease.

Systematic use of post-chemotherapy surgery in responsive patients was of main importance in the latter two studies (69, 70) (level of evidence: 2a).

In addition, a preliminary report (71) on taxol combined with PF (TPF) chemotherapy in six consecutive patients with unresectable or relapsed inguinopelvic lymph node metastases from SCC of the penis suggests that TPF could have improved activity compared to PF alone in this clinical situation (65), as has been demonstrated in SCC of the head and neck in three randomised trials (72-74).

In conclusion, adjuvant chemotherapy is strongly recommended in pN2-3 patients, and neo-adjuvant chemotherapy with taxanes seems to be active in unresectable or recurrent lymph node metastases (level of evidence: 2a, grade of recommendation: B).

8.2.5 The role of radiotherapy
Prophylactic radiotherapy in clinical N0 patients is not recommended for the following reasons:
• radiotherapy fails to prevent the development of metastatic lymph nodes (75)
• complications of radiotherapy (76)
• follow-up is more difficult due to fibrotic changes.

Pre-operative radiotherapy in patients with fixed nodes can make the nodes operable, but it is not known whether node fixation is an inflammatory reaction or malignant growth (75, 76). Adjuvant radiotherapy may improve loco-regional control in patients with extensive metastases and/or extranodal spread. However, severe side-effects include oedema and pain (75).
8.2.6 Guidelines for treatment strategies for nodal metastases

<table>
<thead>
<tr>
<th>Regional lymph nodes</th>
<th>Management of regional lymph nodes is fundamental in the treatment of penile cancer</th>
<th>LE</th>
<th>GR</th>
</tr>
</thead>
<tbody>
<tr>
<td>No palpable inguinal nodes</td>
<td>Tis, Ta G1, T1G1: surveillance</td>
<td>2a</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td>&gt; T1G2: DSNB (NB: Inguinal LAD if histology is positive.)</td>
<td>2a</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td>If DSNB not available: risk factors / nomogram decision-making</td>
<td>3</td>
<td>C</td>
</tr>
<tr>
<td>Palpable inguinal nodes</td>
<td>Ultrasound-guided FNAB (NB: DSNB is unsuitable for palpable nodes)</td>
<td>2a</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td>Negative biopsy: surveillance (repeat biopsy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Positive biopsy: inguinal LAD on positive side (NB: Modified LAD must include the central zone and both superior Daseler’s zones.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pelvic nodes</td>
<td>Pelvic LAD if there are: extranodal metastases; Cloquet node involved; &gt; 2 inguinal node metastases</td>
<td>2a</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td>Unilateral pelvic LAD if unilateral lymph node metastases with prolonged inguinal incision</td>
<td>2b</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td>Bilateral pelvic LAD if bilateral inguinal metastases</td>
<td>2a</td>
<td>B</td>
</tr>
<tr>
<td>Adjuvant chemotherapy</td>
<td>In patients with &gt; 1 intranodal metastasis (pN2 pN3) after radical LAD, survival is improved by adjuvant chemotherapy (2 or 3 courses of cisplatin, fluorouracil (PF) chemotherapy)</td>
<td>2b</td>
<td>B</td>
</tr>
<tr>
<td>Patients with fixed or relapsed inguinal nodes</td>
<td>Neo-adjuvant chemotherapy is strongly recommended in patients with unresectable or recurrent lymph node metastases. Taxanes seems to improve the efficacy of standard PF chemotherapy</td>
<td>2a</td>
<td>B</td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>Curative radiotherapy may be used for primary tumours of the glans penis and sulcus &lt; 4 cm or for palliation</td>
<td>2a</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td>Prophylactic radiotherapy in clinical N0 patients is not indicated</td>
<td>2a</td>
<td>B</td>
</tr>
</tbody>
</table>

LE = level of evidence; GR = grade of recommendation; LAD = lymphadenectomy; FNAB = fine-needle aspiration biopsy; DSNB = sentinel node biopsy.

8.3 REFERENCES

UPDATE MARCH 2009


UPDATE MARCH 2009 25


9. FOLLOW-UP

Follow-up in penile carcinoma is important for several reasons:

- It enables early detection of recurrence, which is important because most local and/or loco-regional recurrences are potentially curable.
- It is the only way to assess treatment and anticipate early and late complications.
- It is also important for patient (and physician) education.

A rational follow-up scheme requires an understanding of the patterns of recurrence. Preferably, follow-up should be introduced within the framework of a randomised study. Based on a retrospective study, a follow-up schedule for penis cancer has been published (1).

9.1 How to follow-up

The aim of follow-up is to detect local and/or regional recurrences because they may be cured. In contrast, metastases at distant sites are always fatal (2). Risk stratification for recurrence is also helpful. Traditional follow-up methods have been inspection and physical evaluation. Modern ultrasound imaging is a useful adjunct, with promising results from new imaging modalities, such as PET scan and laser-directed MRI (3).

9.2 When to follow-up

The follow-up interval and strategies for patients with penile cancer are directed by the initial treatment of the primary lesion and regional lymph nodes. In the above-mentioned multicentre study (1), during the first 2 years of follow-up, the following occurred:

- 74.3% of all recurrences
- 66.4% of local recurrences
- 86.1% of regional recurrences
- 100% of distant recurrences.

Of all recurrences, 92.2% occurred within the first 5 years (1). All recurrences after 5 years were local recurrences or new primaries. Thus, an intensive programme of follow-up during the first 2 years is rational with less intensive follow-up needed thereafter. In well-educated and motivated patients, follow-up can stop after 5 years, although they must continue to carry out regular self-examination.

9.3 Primary tumour

Local recurrence has been reported in up to 30% of patients treated with penile-preserving surgery, during the first 2 years following treatment. Local recurrence is more likely with all types of local therapy, i.e. local resection, laser therapy, BRT, Mohs’ procedure, and associated therapies (1, 4). However, in contrast to regional recurrences, local recurrences do not impact on survival (1, 4).

Local recurrences are easily detected by the patient, his partner or doctor. Patient education is an important part of follow-up and the patient should be urged to visit a specialist if any changes are seen. Despite the fact that late local recurrences are well documented, it is reasonable to stop follow-up after 5 years, provided the patient will report local changes immediately (5). This is possible because life-threatening regional and distant metastases no longer occur, while recurrences that are local only are not life-threatening. The emphasis should be placed on patient self-examination.

In patients who are unlikely to self-examine, long-term follow-up may be necessary.

Following penile-preserving treatment, a follow-up visit every 3 months is advised in the first 2 years. We then advise a follow-up visit every half year, provided that the patient and partner have been well instructed to examine the penis regularly and to return if any abnormality is observed. It is important to stress that the patient must continue to carry out regular self-examination even after 5 years’ follow-up.

After amputation, a less frequent time interval of every 6 months is advised. The risk of local recurrence is not more than 5% (1, 4).

9.4 Regional recurrences

Stringent follow-up is advised for the 2 years following surgery. This is because most regional recurrences occur within 2 years, whether a ‘wait-and-see’ policy has been followed or the patient has undergone SNB or inguinal LAD.

Previous follow-up recommendations have relied heavily on physical examination of the inguinal regions. However, experience with ‘wait and see’ and dynamic SNB have shown that, despite intensive follow-up, regional recurrences have shown up unexpectedly (6). Ultrasound and immediate fine-needle aspiration...
have been encouraging in finding occult metastases (6, 7) and it seems reasonable to add ultrasound to a physical examination.

Patients managed with a ‘wait-and-see’ policy have a higher risk of recurrence (9%) than patients staged surgically (2.3%), whether staging has been performed by LAd or dynamic SNB. This finding only applies to patients without histopathological evidence of lymph node metastases.

Patients treated surgically because of lymph node metastases have an increased risk of recurrence (19%) (1). Based on these findings, a change in the follow-up scheme is proposed. For patients in a ‘wait-and-see’ programme and patients given LAd for proven lymph node metastases, follow-up should be every 3 months and should include ultrasound investigation of the groin. This intensive follow-up programme should be for 2 years, which is the period when recurrence is most likely. Imaging using CT has been replaced by ultrasound scanning with immediate fine-needle aspiration biopsy, although CT scans are still used in patients with a regional recurrence. So far, other imaging modalities have not proven reliable at detecting pelvic and retroperitoneal recurrences.

Bone scan and other tests are only recommended in symptomatic patients. The role of PET scan is unclear and therefore not advised as a routine procedure.

9.5 Guidelines for follow-up in penile cancer

Table 8 provides a follow-up schedule for penile cancer with grades of recommendation.

Table 8: Follow-up schedule for penile cancer

<table>
<thead>
<tr>
<th>Interval of follow-up</th>
<th>Examinations and Investigations</th>
<th>Maximum length of follow-up</th>
<th>GR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Years 1 and 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Years 3, 4 and 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Recommendations for follow-up of primary tumour</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penile-preserving treatment</td>
<td>3 months</td>
<td>6 months</td>
<td>Regular physician or self-examination</td>
</tr>
<tr>
<td>Amputation</td>
<td>6 months</td>
<td>1 year</td>
<td>Regular physician or self-examination</td>
</tr>
<tr>
<td><strong>Recommendations for follow-up of the inguinal lymph nodes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>‘Wait-and-see’</td>
<td>3 months</td>
<td>6 months</td>
<td>Regular physician or self-examination Ultrasound with FNAB</td>
</tr>
<tr>
<td>pN0</td>
<td>6 months</td>
<td>1 year</td>
<td>Regular physician or self-examination Ultrasound with FNAB</td>
</tr>
<tr>
<td>pN+</td>
<td>3 months</td>
<td>6 months</td>
<td>Regular physician or self-examination Ultrasound with FNAB</td>
</tr>
</tbody>
</table>

GR = grade of recommendation; FNAB = fine-needle aspiration biopsy.

9.6 REFERENCES


10. QUALITY OF LIFE

10.1 Sexuality and fertility after cancer
As more people achieve long-term survival after cancer, sexual dysfunction and infertility are increasingly recognized as negative consequences affecting quality of life (1).

10.1.1 Sexual activity and quality of life after penile cancer laser treatment
A retrospective, face-to-face, structured interview study was carried out on Swedish patients treated with laser for localized penile carcinoma during 1986 to 2000 (2). Sixty-seven patients were treated, with 58 of them (mean age 63 years) still alive in 2006. Forty-six (79%) agreed to participate in the interview. Nearly all patients could recall their first symptom, with 37% reporting that they delayed seeking treatment for more than 6 months. Patients had a greater lifetime number of sexual partners and a greater lifetime prevalence of sexually transmitted infections than the comparable general Swedish population. Following laser treatment, there was a marked decrease in some sexual practices, such as manual stimulation or caressing and fellatio. Patient satisfaction with life overall was similar to that of the general population.

In conclusion, some patients delayed seeking treatment for a considerable period despite awareness of the first local symptoms. Men with laser-treated localized penile carcinoma resumed their sexual activities to a large extent. Except for satisfaction with somatic health, a similar (or higher) proportion of patients were satisfied with life overall and with other domains of life including sexual life.

10.1.2 Sexual function after partial penectomy for penile cancer
To compare sexual function and satisfaction before and after partial penectomy, 18 Brazilian patients were given a personal interview and answered the International Index of Erectile Function (IIEF) questionnaire to determine erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction with sexual life (3). The median patient age was 52 years. The medium penile length after partial penectomy was 4 cm in the flaccid state, with 55.6% of patients reporting erectile function that allowed sexual intercourse. The main reason given for not resuming sexual intercourse in 50% of sexually abstinent patients was feeling shame because of a small penis and the absence of the glans penis. Surgical complications also compromised resumption of sexual activity after amputation in 33.3% of these patients. However, 66.7% sustained the same frequency and level of sexual desire prior to surgery and 72.2% continued to have ejaculation and orgasm every time they had sexual stimulation or intercourse. Nevertheless, only 33.3% maintained their pre-operative sexual intercourse frequency and were satisfied with their sexual relationships with their partners and their overall sex life. In conclusion, the pre-operative and post-operative scores were statistically worse for all domains of sexual function after partial penectomy.

10.2 Sexual mutilation, relapse and death
Today, nearly 80% of penile cancer patients can be cured. Experience in management of this rare tumour is helpful (4). Referral to centers with experience is recommended.

 Psychological support is very important for these patients. Penile-sparing surgery obviously allows a better quality of life than penile amputation and must be considered whenever feasible.
10.3 REFERENCES


11. ABBREVIATIONS USED IN THE TEXT

This list is not comprehensive for the most common abbreviations.

- BMP: cisplatin, methotrexate and bleomycin
- BRT: brachytherapy
- CT: computed tomography
- DSNB: dynamic sentinel node biopsy
- EAU: European Association of Urology
- ERT: external beam irradiation
- FDA: US Food and Drug Administration
- FNAB: fine-needle aspiration biopsy
- HDR: high-dose rate (brachytherapy)
- HPV: human papillomavirus
- IIEF: International Index of Erectile Function questionnaire
- ITP: paclitaxel, ifosfamide and cisplatin
- LAD: lymphadenectomy
- LDR: low-dose rate (brachytherapy)
- MRI: magnetic resonance imaging
- NCI: National Cancer Institute
- Nd-YAG: neodymium:yttrium-aluminum-garnet
- PC: paclitaxel and carboplatin
- PDQ: physician data query
- PDR: pulse-dose rate (brachytherapy)
- PET: positron emission tomography
- PF: cisplatin and fluorouracil
- PGE1: prostaglandin E1 (alprostadil)
- SCC: squamous cell carcinoma
- SNB: sentinel node biopsy
- SWOG: Southwest Oncology Group
- 99mTC: technetium 99m
- TNM: tumour, node, metastasis
- TPF: taxanes combined with PF (cisplatin and fluorouracil)
- VBM: vinblastine, bleomycin, methotrexate

Conflict of interest

All members of the Penile Cancer Guidelines writing panel have provided disclosure statements on all relationships that they have and that might be perceived to be a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.